New Potential Personalized Medicine Platform

p-medicine project, launched in February this year, is a 4-year Integrated project aiming at developing a new and state-of-the-art IT platform for personalized medicine. The researchers elaborated the first deliverables according to the agreed 'Description of Work', they identified and described motivated use case scenarios by underlining the p-medicine platform's end user needs and requirements.

"It is the purpose of p-medicine to deliver an architecture that will allow to drive medicine to more individualized treatments based on exploiting the vast amount of heterogeneous data of single patients by software, services, tools and models that will support physicians in decision making in their daily care of patients," said p-medicine project coordinator Prof. Dr. Norbert Graf, Director of the Department of Pediatric Oncology and Hematology, Saarland University (Germany).

"All presented use-case scenarios have been actively discussed and only the mutually agreed versions have been considered," added Prof. Graf, who helped elaborate the first project deliverables while contributing and coordinating the input from all project partners.

"Project partners demonstrated a strong commitment and an active enrolment. The p-medicine project is an interdisciplinary and collaborative research activity. One of the learnt lessons is: we are in the right direction with high skilled and experienced partners," concluded Prof. Graf.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to enable support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized treatment of cancer. p-medicine unifies European experts in different fields (clinicians, biologists, IT-specialists, ethical and legal experts) to develop and exploit data and tools that support translational research in every aspect.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
The European Integrated Project p-medicine is supported by the European Commission under the 7th Framework Programme, Grant agreement number 270089.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...